Successful Desensitization of a Patient with Rituximab Hypersensitivity
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid d...
Saved in:
Main Authors: | Pinar Ataca, Erden Atilla, Resat Kendir, Sevim Bavbek, Muhit Ozcan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Case Reports in Immunology |
Online Access: | http://dx.doi.org/10.1155/2015/524507 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Desensitization of delayed-type hypersensitivity in mice: suppressive environment
by: Takashi Katsura, et al.
Published: (1993-01-01) -
Successful desensitization with 5-fluorouracil in a patient who developed anaphylaxis after 5-fluorouracil infusion
by: Mehmet Erdem Çakmak, et al.
Published: (2024-08-01) -
Lymphomatoid Granulomatosis Treated Successfully with Rituximab in a Renal Transplant Patient
by: Cindy Castrale, et al.
Published: (2011-01-01) -
Desensitization: Overcoming the Immunologic Barriers to Transplantation
by: Supreet Sethi, et al.
Published: (2017-01-01) -
The experiences of ferric carboxymaltose desensitization and provocation
by: Fatma Dindar Çelik, MD, et al.
Published: (2025-02-01)